Maia Biotechnology

Last updated
Maia Biotechnology
IndustryBiotechnology, medicine
Key people
Vlad Vitoc (CEO, chairman), Sergei M. Gryaznov (Chief Scientific Officer)
Website maiabiotech.com

Maia Biotechnology is a public, Texas based, immune-oncology company. [1]

Contents

History

In August 2022, the company's initial funding round closed, raising $10M. [2]

In March 2024, the company's equity fell below $500,000. [3] In April 2024, the company announced the completion of a $1 million private placement. [4]

Clinical trials

Phase II THIO-101

A phase II THIO-101 clinical trial of THIO sequenced with cemiplimab to treat advanced non-small cell lung cancer (NSCLC). The trial is a multicentre, open-label, dose-finding trial designed to assess anti-tumour activity followed by PD-L1 inhibition. The study population was patients with advanced NSCLC who did not respond or developed resistance to first-line treatments using another checkpoint inhibitor. The trial's primary objectives are to assess tolerability, safety, and clinical efficacy using overall response rate (ORR) as the primary endpoint. [5]

In 2025, the FDA "Rare Pediatric Disease Designation" for THIO in treating pediatric-type diffuse high-grade gliomas (PDHGG), making MAIA eligible for a priority review voucher upon future FDA approval. [6]

Drug candidates

THIO (6-thio-2'-deoxyguanosine) is a drug that attempts to kill cells that express telomerase, which is found in 85% of human cancers. [1]

See also

References

  1. 1 2 Wang, Brian (2024-06-05). "Promising Possible Universal Cancer Treatment". NextBigFuture. Retrieved 2024-06-11.
  2. ↑ Cornall, Jim (2022-08-02). "MAIA Biotechnology raises $10M from public offering". Labiotech.eu. Retrieved 2024-06-11.
  3. ↑ "MAIA Biotechnology at Risk of NYSE Delisting Over Equity Shortfalls - TipRanks.com". TipRanks Financial. Retrieved 2024-06-11.
  4. ↑ "MAIA Biotechnology Announces $1.00 Million Private Placement". BioSpace. Retrieved 2024-06-11.
  5. ↑ Priyan, Vishnu (2024-03-07). "MAIA Biotechnology reports positive data from NSCLC therapy trial". Clinical Trials Arena. Retrieved 2024-06-11.
  6. ↑ "FDA grants Rare Pediatric Disease designation for THIO in pediatric high-grade gliomas". The Cancer Letter. January 17, 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.